Gabapentin
Product Images NDC 66116-407

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 66116-407). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Medvantx, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (38d9d7d7 9f81 4517 Acee E34232215800 01)

FDA Label Image

Figure 1. Weekly Mean Pain Scores (observed Cases In Itt Population): Study 1 (38d9d7d7 9f81 4517 Acee E34232215800 02)

FDA Label Image

Figure 2. Weekly Mean Pain Scores (observed Cases In Itt Population): Study 2 (38d9d7d7 9f81 4517 Acee E34232215800 03)

Figure 2. Weekly Mean Pain Scores (observed Cases In Itt Population): Study 2 (38d9d7d7 9f81 4517 Acee E34232215800 03)
This is a study report showing the mean pain score over a period of 7 weeks. The study involved a 3-week dose titration period followed by a fixed dose period. The study included a placebo group and two groups receiving Gabapentin at doses of 1800 mg/day and 2400 mg/day. The mean pain scores were significantly lower for the Gabapentin groups than for the placebo group (p<0.01).*
FDA Label Image

Figure 3. Proportion Of Responders (patients With ≥50% Reduction In Pain Score) At Endpoint: Controlled Phn Studies (38d9d7d7 9f81 4517 Acee E34232215800 04)

Figure 3. Proportion Of Responders (patients With ≥50% Reduction In Pain Score) At Endpoint: Controlled Phn Studies (38d9d7d7 9f81 4517 Acee E34232215800 04)
The text provides statistical results related to the percentage of responders at endpoint for two studies. One of the studies shows a p-value of less than 0.001 and the other shows a p-value of less than 0.0001. No further information or context is provided.*
FDA Label Image

Figure 4. Responder Rate In Patients Receiving Gabapentin Expressed As A Difference From Placebo By Dose And Study (38d9d7d7 9f81 4517 Acee E34232215800 05)

FDA Label Image

Gabapentin 300mg 60 Capsules (38d9d7d7 9f81 4517 Acee E34232215800 06)

Gabapentin 300mg 60 Capsules (38d9d7d7 9f81 4517 Acee E34232215800 06)
This is a medication label for Gabapentin capsules, USP. The dosage information is in the package insert. The medication should be taken every few hours and should not be allowed to run out. The capsules are 300mg and the lot number is 00000000. The expiration date is not stated. Storage should be at 20°-25°C (68°-77°F), and the container should be kept tightly closed. The label includes the contact details for Medvant and advises to keep the medication out of reach of children.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.